Literature DB >> 21858729

Matrix metalloproteinase-1 expression enhances tumorigenicity as well as tumor-related angiogenesis and is inversely associated with TIMP-4 expression in a model of glioblastoma.

Nicholas A Pullen1, Monika Anand, Patricia S Cooper, Helen L Fillmore.   

Abstract

Herein we continue the study of matrix metalloproteinase-1 (MMP-1) with respect to glioblastoma multiforme (GBM) cell tumorigenicity and angiogenesis. A model of tumorigenicity with cells stably altered to over-express or knock-down MMP-1 revealed that it significantly increases tumor incidence and size. Organized endothelial growth in human umbilical vein endothelial cell (HUVEC)-GBM co-cultures was significantly increased in the presence of MMP-1. CD31 analysis of model tumors elucidated a substantial recruitment of endothelium in MMP-1 enhanced samples. Antibody arrays indicated an inverse expression of certain anti-angiogenic factors with respect to MMP-1, the most notable of which was a significant increase in tissue inhibitor of metalloproteinases-4 (TIMP-4) in the absence of MMP-1, as validated by immunoblot.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21858729     DOI: 10.1007/s11060-011-0691-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  41 in total

1.  TIMP-2 is required for efficient activation of proMMP-2 in vivo.

Authors:  Z Wang; R Juttermann; P D Soloway
Journal:  J Biol Chem       Date:  2000-08-25       Impact factor: 5.157

Review 2.  Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy.

Authors:  Tanya A Rege; Constance Y Fears; Candece L Gladson
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

Review 3.  Gelatinase-mediated migration and invasion of cancer cells.

Authors:  Mikael Björklund; Erkki Koivunen
Journal:  Biochim Biophys Acta       Date:  2005-04-12

4.  A novel host/tumor cell interaction activates matrix metalloproteinase 1 and mediates invasion through type I collagen.

Authors:  U Benbow; M P Schoenermark; T I Mitchell; J L Rutter; K Shimokawa; H Nagase; C E Brinckerhoff
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

Review 5.  Molecular mechanisms of glioma invasiveness: the role of proteases.

Authors:  Jasti S Rao
Journal:  Nat Rev Cancer       Date:  2003-07       Impact factor: 60.716

6.  Induction of matrix metalloproteinase-1 and glioma cell motility by nitric oxide.

Authors:  Nicholas A Pullen; Helen L Fillmore
Journal:  J Neurooncol       Date:  2009-07-21       Impact factor: 4.130

7.  Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.

Authors:  Véronique Mathieu; Nancy De Nève; Marie Le Mercier; Janique Dewelle; Jean-François Gaussin; Mischael Dehoux; Robert Kiss; Florence Lefranc
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

8.  Vascular regression and survival are differentially regulated by MT1-MMP and TIMPs in the aortic ring model of angiogenesis.

Authors:  A C Aplin; W H Zhu; E Fogel; R F Nicosia
Journal:  Am J Physiol Cell Physiol       Date:  2009-06-03       Impact factor: 4.249

Review 9.  Epidemiology of brain tumors.

Authors:  James L Fisher; Judith A Schwartzbaum; Margaret Wrensch; Joseph L Wiemels
Journal:  Neurol Clin       Date:  2007-11       Impact factor: 3.806

10.  Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts.

Authors:  J Graeme Hodgson; Ru-Fang Yeh; Amrita Ray; Nicholas J Wang; Ivan Smirnov; Mamie Yu; Sujatmi Hariono; Joachim Silber; Heidi S Feiler; Joe W Gray; Paul T Spellman; Scott R Vandenberg; Mitchel S Berger; C David James
Journal:  Neuro Oncol       Date:  2009-01-12       Impact factor: 12.300

View more
  9 in total

1.  Targeting of BMI-1 with PTC-209 inhibits glioblastoma development.

Authors:  Yu Kong; Chunbo Ai; Feng Dong; Xianyou Xia; Xiujuan Zhao; Chao Yang; Chunsheng Kang; Yan Zhou; Qian Zhao; Xiujing Sun; Xudong Wu
Journal:  Cell Cycle       Date:  2018-07-23       Impact factor: 4.534

2.  RUNX1 Regulates Migration, Invasion, and Angiogenesis via p38 MAPK Pathway in Human Glioblastoma.

Authors:  Kant Sangpairoj; Pornpun Vivithanaporn; Somjai Apisawetakan; Sukumal Chongthammakun; Prasert Sobhon; Kulathida Chaithirayanon
Journal:  Cell Mol Neurobiol       Date:  2016-12-24       Impact factor: 5.046

3.  EphrinA1 is released in three forms from cancer cells by matrix metalloproteases.

Authors:  Amanda Beauchamp; Mark O Lively; Akiva Mintz; Denise Gibo; Jill Wykosky; Waldemar Debinski
Journal:  Mol Cell Biol       Date:  2012-06-11       Impact factor: 4.272

Review 4.  Protein biomarkers of epileptogenicity after traumatic brain injury.

Authors:  Denes V Agoston; Alaa Kamnaksh
Journal:  Neurobiol Dis       Date:  2018-07-17       Impact factor: 5.996

5.  CD271 defines a stem cell-like population in hypopharyngeal cancer.

Authors:  Takayuki Imai; Keiichi Tamai; Sayuri Oizumi; Kyoko Oyama; Kazunori Yamaguchi; Ikuro Sato; Kennichi Satoh; Kazuto Matsuura; Shigeru Saijo; Kazuo Sugamura; Nobuyuki Tanaka
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

6.  Comprehensive analysis of expression, prognosis and immune infiltration for TIMPs in glioblastoma.

Authors:  Jinkun Han; Yajun Jing; Fubing Han; Peng Sun
Journal:  BMC Neurol       Date:  2021-11-15       Impact factor: 2.474

Review 7.  Enhancing T Cell Chemotaxis and Infiltration in Glioblastoma.

Authors:  Kirit Singh; Kelly M Hotchkiss; Kisha K Patel; Daniel S Wilkinson; Aditya A Mohan; Sarah L Cook; John H Sampson
Journal:  Cancers (Basel)       Date:  2021-10-26       Impact factor: 6.639

8.  Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma.

Authors:  Sébastien Bougnaud; Anna Golebiewska; Anaïs Oudin; Olivier Keunen; Patrick N Harter; Lisa Mäder; Francisco Azuaje; Sabrina Fritah; Daniel Stieber; Tony Kaoma; Laurent Vallar; Nicolaas H C Brons; Thomas Daubon; Hrvoje Miletic; Terje Sundstrøm; Christel Herold-Mende; Michel Mittelbronn; Rolf Bjerkvig; Simone P Niclou
Journal:  Oncotarget       Date:  2016-05-31

9.  SCO-spondin oligopeptide inhibits angiogenesis in glioblastoma.

Authors:  Romain Bibes; Stéphane Gobron; François Vincent; Carole Mélin; Nicolas Vedrenne; Aurélie Perraud; Francois Labrousse; Marie-Odile Jauberteau; Fabrice Lalloué
Journal:  Oncotarget       Date:  2017-09-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.